Intrinsiqq
Glaukos Corporation logo

Glaukos Corporation Quality Score

GKOS

⊜ Compare
Quality55

Valuation is the primary weakness (avg 20/100). Growth is the relative bright spot.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
0/100
-83.3x

Negative earnings, no valuation support

Cash Flow Multiple
40/100
405.4x

Above 30x, cash flow yield is thin

Revenue Growth
100/100
25.0%

Above 10% CAGR, strong compounder

Cash Flow Growth
60/100
Just turned +

Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful

Business Quality & Capital Allocation

Share Dilution
0/100
29.0%

Heavy dilution above 5%

Margin Trend
100/100
+3.6pp

Expanded 3+pp, strong improvement

Capital Structure
100/100
-$57M

Net cash position, no leverage concern

2022
$120M
$383M
2023
$93.0M
$386M
2024
$170M
$106M
2025
$91.0M
$107M
TTM
$162M
$105M
CashDebt
Return on Capital
0/100
-17.7%

Below 8%, may not cover cost of capital

Customize WeightsPremiumUpgrade

Glaukos (GKOS) quality: score, margins and returns

Glaukos (GKOS) scores 55/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 6 metrics each scored 0 to 100, on -25.5% operating margins and -17.7% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Glaukos (GKOS) a high-quality business?+

Glaukos scores 55 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a -25.5% operating margin and a -17.7% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Glaukos's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from GKOS's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Glaukos scores well and where it falls behind.

What is Glaukos's return on invested capital (ROIC)?+

Glaukos earns about -17.7% on its invested capital, which is weak. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to GKOS's margins and growth on this scorecard to judge durability.

How profitable is Glaukos?+

Glaukos runs an operating margin of about -25.5% and a net margin of about -24.6%. Revenue has grown at roughly 17.7% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 26 Oct 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 29 Oct 2026. How this is calculated.

Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Surgical & Medical Instruments & Apparatus · Pick stocks to compare with GKOS

CompareIntrinsic value
NVCRNovoCure Ltd.
$14.61+8.79%24
UFPTUFP Technologies Inc.
$329.82+17.66%40
BVSBioventus Inc.
$11.42+4.34%66
ATRCAtriCure, Inc.
$65.53+8.48%65
ATECAlphatec Holdings Inc.
$8.28+10.84%45
IRTCIrhythm Technologies Inc.
$134.00+6.04%45
OFIXOrthofix Medical Inc.
$9.72+10.96%18
INSPInspire Medical Systems, Inc.
$66.61+7.61%81

Held by ETFs

GKOS is in 91 US ETFs. The largest of them, with GKOS's weight in each:

Spot a number that looks wrong? Check it in GKOS's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing GKOS

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.